OTC · Financial Statements
HLS Therapeutics Inc. (HLTRF) Financial Statements
$2.98
OTC: HLTRF
Market Cap $93.20M
Overview Financials Dividend
HLS Therapeutics Inc. most recently reported annual revenue of $56.0M, a net loss of $13.0M. Revenue was roughly flat over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $60.0M $61.0M $63.0M $57.0M $56.0M Operating Profit $-6.0M $-13.0M $-10.0M $-8.0M $-4.0M Net Profit $-13.0M $-24.0M $-28.0M $-20.0M $-13.0M EPS $-0.41 $-0.73 $-0.85 $-0.62 $-0.40 Op Margin -10.5% -21.9% -16.4% -13.6% -7.4%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $276.0M $242.0M $209.0M $160.0M $137.0M Total Liabilities $115.0M $116.0M $111.0M $89.0M $76.0M Cash $21.0M $21.0M $22.0M $17.0M $12.0M Borrowings $98.0M $97.0M $88.0M $66.0M $50.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $16.0M $17.0M $16.0M $8.0M $16.0M Investing Cash Flow $-9.0M $-30.0M $0 $12.0M $-2.0M Financing Cash Flow $5.0M $-1.0M $-3.0M $-2.0M $-2.0M Net Cash Flow $1.0M $0 $1.0M $-4.0M $-6.0M Free Cash Flow $12.0M $7.0M $16.0M $8.0M $16.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.15 EV / EBITDA 7.02 FCF Yield 19.75% Quick Ratio 0.75 Interest Coverage -0.70 Return 1Y -16.53% Return 3Y -37.26% Return 5Y -77.77%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .